Publication:

A neuroprotective agent that inactivates prodegenerative TrkA and preserves mitochondria

Loading...
Thumbnail Image

Open/View Files

Date

2017

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Rockefeller University Press
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Feinberg, Konstantin, Adelaida Kolaj, Chen Wu, Natalie Grinshtein, Jonathan R. Krieger, Michael F. Moran, Lee L. Rubin, Freda D. Miller, and David R. Kaplan. 2017. “A neuroprotective agent that inactivates prodegenerative TrkA and preserves mitochondria.” The Journal of Cell Biology 216 (11): 3655-3675. doi:10.1083/jcb.201705085. http://dx.doi.org/10.1083/jcb.201705085.

Abstract

Axon degeneration is an early event and pathological in neurodegenerative conditions and nerve injuries. To discover agents that suppress neuronal death and axonal degeneration, we performed drug screens on primary rodent neurons and identified the pan-kinase inhibitor foretinib, which potently rescued sympathetic, sensory, and motor wt and SOD1 mutant neurons from trophic factor withdrawal-induced degeneration. By using primary sympathetic neurons grown in mass cultures and Campenot chambers, we show that foretinib protected neurons by suppressing both known degenerative pathways and a new pathway involving unliganded TrkA and transcriptional regulation of the proapoptotic BH3 family members BimEL, Harakiri,and Puma, culminating in preservation of mitochondria in the degenerative setting. Foretinib delayed chemotherapy-induced and Wallerian axonal degeneration in culture by preventing axotomy-induced local energy deficit and preserving mitochondria, and peripheral Wallerian degeneration in vivo. These findings identify a new axon degeneration pathway and a potentially clinically useful therapeutic drug.

Description

Research Data

Keywords

Article

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories